anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Albendazole is an orally administered anthelmintic drug. Chemically, it is methyl 5-(propylthio)-2-benzimidazolecarbamate. Its molecular formula is C12H15N3O2S. Its molecular weight is 265.34. It has the following chemical structure:

Albendazole USP is a white to slightly yellowish or faintly yellowish powder. It is practically insoluble in water, freely soluble in anhydrous formic acid, very slightly soluble in methylene chloride, practically insoluble in ethanol 96 %v/v.

Each tablet is white to off white, film-coated, round biconvex with beveled edges is debossed with "452" on one side and plain other side 

Inactive ingredients consist of: corn starch, hypromellose 2910 (15 mPas), hypromellose 2910 (5 mPas), lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, propylene glycol, saccharin sodium, sodium lauryl sulfate, and sodium starch glycolate. 

FDA approved dissolution test method differs from the USP dissolution test method.
A plurality of coordinates are mapped to respective first voxels. Each first voxel is assigned a value f(0), f(n) being a monotonic function defined between 0 and M inclusive. A plurality of second voxels {v i }, each of which is at a distance 1≤d(v i )≤M voxels from a nearest first voxel, are assigned respective second values {f(d(v i ))}. Each of at least some of the second voxels is then iteratively assigned a weighted average of respective values of its immediate neighbors, any value differing from f(M) by not more than a first threshold being given a higher weight than any other value. A subset of the second voxels, each of which has a value differing from f(M) by more than a second threshold, are identified. Subsequently, a mesh representing a surface of a volume including the first voxels and the subset of the second voxels is generated.
5-Phenyl-2-methylimino-4-oxazolidinone is prepared by the reaction of 5-phenyl-2-imino-4-oxazolidinone with a methylating agent, e.g. dimethyl sulphate, methyl iodide, methyl bromide or methyl p-toluenesulphonate, in the presence of an acid acceptor. In the specific example dimethyl sulphate is used in sodium methoxide/methanol.ALSO:Pharmaceutical compositions in unit dosage form having a stimulant effect on the mammalian central nervous sytem comprise a carrier and 5 - phenyl - 2 - methylimino - 4-oxazolidinone which in one tautomeric form has the structure <FORM:0912977/VI/1> or an acid addition salt thereof.  The compositions may be in forms suitable for oral, rectal and parenteral administration e.g. a tablet, dragee, capsule, drops, emulsions, suspension, syrup, candy, chewing gum or suppository.  Unit dosage forms may comprise between about 1 and 100 m.g. of the active compound.
This study aimed to summarize our experience with modified drilling epiphysiodesis and prediction methods for accurate timing of surgery and to compare the results with those of recent work by other authors. The Macnicol and Gupta modified drilling technique was used. Distal femoral and/or proximal tibial permanent epiphysiodesis was performed in 42 children (21 boys, 21 girls; median age at surgery=12.6 years, age range=9.4-15.4 years) between 2004 and 2016. Based on the groundwork of previous studies, we developed an auxological prediction method. The limb length discrepancy (LLD) was assessed by clinical examination and verified by an x-ray of the hips when standing with blocks under the shorter leg. The predicted shortening was 2.7 cm ± 1.1 cm. The final discrepancy after finishing skeletal growth was 0.5 ± 0.5 cm. In 26 patients (61.9%), equalization of both legs was achieved (0-0.5 cm). In 4 patients (9.5%), the remaining shortening was more than 1.0 cm. Shortening of an initially longer leg occurred in two patients (0.5 cm and 0.6 cm). Failure of growth plate arrest was observed in 1 patient. In another 3 patients, the efficacy of tibial epiphysiodesis was unsatisfactory. Minor complications occurred in 5 cases, but there was no evidence of angular deformity in the frontal and sagittal planes or proximal fibula overgrowth. Three patients (7.1%) returned to the operating room. Compared to published data, more patients achieved complete equalization of leg length. The results of this study verified the accuracy of the auxological prediction algorithm of LLD based on Shapiro's findings. The surgical outcome is comparable between Shapiro patterns 1 and 3. Auxological examination, assessment of bone age, and sexual maturation are crucial tools for accurate timing of surgery.
Risk Summary

The limited human data with tiotropium bromide inhalation powder use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. Based on animal reproduction studies, no structural abnormalities were observed when tiotropium was administered by inhalation to pregnant rats and rabbits during the period of organogenesis at doses 790 and 8 times, respectively, the maximum recommended human daily inhalation dose (MRHDID). Increased post-implantation loss was observed in rats and rabbits administered tiotropium at maternally toxic doses 430 times and 40 times the MRHDID, respectively [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

In 2 separate embryo-fetal development studies, pregnant rats and rabbits received tiotropium during the period of organogenesis at doses up to approximately 790 and 8 times the MRHDID, respectively (on a mcg/m2 basis at inhalation doses of 1471 and 7 mcg/kg/day in rats and rabbits, respectively). No evidence of structural abnormalities was observed in rats or rabbits. However, in rats, tiotropium caused fetal resorption, litter loss, decreases in the number of live pups at birth and the mean pup weights, and a delay in pup sexual maturation at tiotropium doses of approximately 40 times the MRHDID (on a mcg/m2 basis at a maternal inhalation dose of 78 mcg/kg/day). In rabbits, tiotropium caused an increase in post-implantation loss at a tiotropium dose of approximately 430 times the MRHDID (on a mcg/m2 basis at a maternal inhalation dose of 400 mcg/kg/day). Such effects were not observed at approximately 5 and 95 times the MRHDID, respectively (on a mcg/m2 basis at inhalation doses of 9 and 88 mcg/kg/day in rats and rabbits, respectively).
Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.
Phase 5 evaluated even greater bortezomib dosing density by eliminating the inter-cycle dosing interval. Phase 5 evaluated eight consecutive doses of bortezomib with one dose of rituximab. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patient will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, 11, 14, 17, 20, and 23. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
Participants who completed the DEP were randomized 1:1 to receive SYNB1934v1 at their iTD established in the DEP orally immediately after meals. Participants remained on this dose of SYNB1934v1 for the duration of the RWP; doses of SYNB1934v1 were not permitted to be modified during the RWP.
Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided. The key to these conjugates is a special spacer connecting at least one photosensitizer to a microorganism receptor (vector) which in turn binds selectively to the surface of a microorganism bringing about photo-destruction upon irradiation. Spacers having hydrophilic structure such as ethylene glycol units and amino carboxyl end capped ethylene glycol units must be used for linking the vector to the photosensitizer. In a preferred embodiment a spacer would have at least 3 ethylene glycol units and be end capped with a carboxyl group on one end and a amino group at the other end. The present invention effectively works to combat bacterial infection in the real patient-related environments where blood, serum and other body fluids are always present or at least nearby of selected length and structure, in preferred embodiments, are used for linking the vector to the photosensitizer. These conjugate are found to be very effective in combating bacterial infection in the real patient-related environments where blood, serum and other body fluids are always present or a least nearby. A method of use is also provided.
ABSTRACT           A process for the isolation and purification of immunologically active polyribosyl ribitol phosphate (PRP), the capsular polysaccharide of Haemophilus influenzae type b. The PRP has been purified with ethanol, Cetavlon (hexadecyl-trimethyl ammonium bromide) and a phosphate containing adsor-bent, hydroxylapatite.  The contaminants (nucleic acid, pro-teins and endotoxins) are removed to the minimum level by a treatment with hydroxylapatite.  Also described is a process for the preparation of a combined vaccine containing the PRP (prepared as forementioned) and B. pertussis antigens. The vaccine elicits anti-PRP antibody and anatipertussis anti-body (as measured by microagglutination) formations in young animals.  This sera with anti-PRP antibody exhibits a strong bactericidal activity.
BACKGROUND: Central pain, characterized by neuropathic pain, can manifest due to injury to the superior spinothalamic tract. The brainstem includes sensory and motor pathways as well as nuclei of the cranial nerves, and therefore cancer metastasis in the region requires early intervention. Although stereotactic radiosurgery (SRS) is commonly employed for the treatment of brain metastasis, it poses risks of late complications like radiation necrosis (RN). RN exacerbates the progression of brain lesions within the irradiated area, and in the brainstem, it can damage multiple nerves, including the superior spinothalamic tract. Central neuropathic pain is often intractable and empirically managed with a combination of conventional drugs, such as serotonin-norepinephrine reuptake inhibitors (SNRIs) and anticonvulsants. However, their efficacy is often limited, leading to a decline in performance status (PS) and quality of life (QOL).
CASE PRESENTATION: We present the case of a 53-year-old man diagnosed with stage IV lung cancer, referred to our palliative care team for managing severe central pain resulting from SRS-related RN in the pons. Despite administration of opioids, including oxycodone and hydromorphone, and adjuvant analgesics, the patient continued to require frequent use of immediate-release opioids. The addition of methadone alone proved successful in achieving optimal pain control.
CONCLUSIONS: Provided that RN in the brainstem can lead to intractable neuropathic pain, it is advisable to avoid SRS for brainstem metastasis when possible. Add-on methadone should be considered as a viable pain management medication for patients experiencing unresolved central pain.
A control group composed of women with normal ovarian reserve (30 to 45 yerras old) is needed to compare telomeric and fertility parameters with the group of women with compromised ovarian reserve. Note that the term "normal ovarian reserve" referred to older women indicates women that still have follicles in their ovaries -and thus, normal AMH values-, even though the number may be lower tan at a younger age or the quality of oocytes may be lower tan in younger women. In other words, women in the control group irrespective of their age, will have a greater number of follicles compared to women belonging to the group with compromised ovarian reserve.
A delivery device includes first and second housing portions that selectively engage and disengage. A reservoir on one housing portion operatively engages a drive device and/or a needle inserting device on the other housing portion. Upon proper engagement of the housing portions, the reservoir operatively couples to the drive device and/or the needle inserting device. A first magnet on the first housing portion and a second magnet (or a magnetically-attractive material) on the second housing portion are positioned to magnetically interact with each other, upon operative engagement of the housing portions. A third magnet on the second housing portion may be opposed to the first magnet to help align the housing portions for connection. A magnet-responsive device may be on one or both housing portions to detect alignment and/or connection of the housing portions.
Participants are given escitalopram for 8 weeks. At week 8, participants will be assessed and classified as "responders" or "non-responders". Responders will continue on escitalopram until the study endpoint (16 weeks).
BACKGROUND: The right comprehension of ischemic stroke pathogenesis guarantees the best prevention therapy. The term "patent foramen ovale (PFO) related stroke" has been proposed for those events where PFO is supposed to be pathogenetic, but their definition is challenging. A multidisciplinary evaluation in a "Heart & Brain" team (HBteam) including stroke neurologists and interventional cardiologists was therefore highly recommended in the recent guidelines of secondary stroke prevention.
OBJECTIVE: We aimed at describing the organization of the HBteam of Careggi-University-Hospital of Florence (Italy), and the results of the first seven years of activity.
METHODS: In 2016 Interventional Cardiologists and Stroke Neurologists set up an outpatient clinic for the joined evaluation of patients with PFO and other cardio/neurological conditions. A specific diagnostic-therapeutic hospital plan was produced for PFO patients. Patient empowerment was guaranteed by a hospital explicative webpage, a booklet regarding risks/benefits of PFO closure and a 3D heartmodel to simulate the intervention. Data were collected in a dedicated registry.
RESULTS: We evaluated 594 patients for PFO, 40 for left atrial appendage closure and 38 for other conditions. In 20% of PFO-patients, HBteam diagnosis was discordant from that of referring physicians, 14% were stroke misdiagnoses. We advised against closure in 53% of patients. At follow-up 94% of closed patients had no/minimum residual shunt; 3 patients had a cerebral ischemic event.
CONCLUSIONS: A dedicated HBteam represents a unique opportunity to share decisions with patients after a thorough empowerment process. The joining of cardioneurological skills allows a better classification of PFO-patients, reducing futile interventions.
This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with hu3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups with a minimum of 3 patients/ dose of NK cells. Three dose levels of NK cells, starting at dose level 1, will be evaluated in this treatment protocol. The goal dose for each dose level is the high boundary (e.g. 9.9x10\^6/kg in level 1; 14.9x10\^6/kg in level 2, etc), but a range is provided to allow for cases where the goal dose cannot be achieved.
Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
Chronic kidney disease in patients with HIV-1 infection treated with atazanavir, with or without ritonavir, has been reported during postmarketing surveillance. Reports included biopsy-proven cases of granulomatous interstitial nephritis associated with the deposition of atazanavir drug crystals in the renal parenchyma. Consider alternatives to REYATAZ in patients at high risk for renal disease or with preexisting renal disease. Renal laboratory testing (including serum creatinine, estimated creatinine clearance, and urinalysis with microscopic examination) should be conducted in all patients prior to initiating therapy with REYATAZ and continued during treatment with REYATAZ. Expert consultation is advised for patients who have confirmed renal laboratory abnormalities while taking REYATAZ. In patients with progressive kidney disease, discontinuation of REYATAZ may be considered [see Dosage and Administration (2.2 and 2.7) and Adverse Reactions (6.2)].
The Experimental groups or physical activity groups were assigned to three groups based on their muscle mass: normal, probable sarcopenia, and sarcopenia groups. The volunteers were provided with instructions on individual physical activities to be practiced at home for 30 weeks, 2-5 days per week and 50 minutes per session. These physical activities consisted of flexibility exercise for 10 minutes, aerobic exercise for 20 minutes, and resistance exercise for 20 minutes, as outlined in supplement 1. The volunteers were instructed on exercise techniques and physical activities by either sports scientists or registered nurses, and caregivers such as relatives or staff from the social club for older adults were allowed to be present during practice.
This is an open label Phase II study. Patients will receive Vidaza for 5 consecutive days (Days 1- 5) of each 28-day cycle. Complete androgen ablation will be continued. Response will be assessed after a minimum of 2 cycles (evaluable patients). PSA response will be evaluated prior to each cycle and % fetal hemoglobin will be evaluated prior to each odd cycle (excluding Cycle 1). Patients will be treated until clinical progression up to a maximum of 12 cycles. A total of 35 patients with advanced metastatic HRPC will be enrolled in this trial.
NEW MATERIAL:A benzimidazole derivative of formula I (R1 is 4-6C alkyl; R2 is methyl). EXAMPLE:2-[2-(N-isobutyl-N-methylamino)benzylsulfinyl]benzimidazole. USE:Useful as an anti-ulcer agent. The compound of formula I has an excellent gastric acid secretion-inhibiting action based on a specific H<+>+K<+>ATPase- inhibiting action thereof and is employed in the preparation of oral or parenteral agents. PREPARATION:A 2-mercapto benzimidazole of formula II is subjected to a reaction a 2-aminobenzyl compound of formula III (R1 is 4-6C alkyl; R2 is methyl; X is a reactive group) preferably in the presence of an alkaline agent in an inactive solvent such as toluene at the room temperature to the reflux temperature of the solution to prepare a compound of formula IV. The compound of formula IV is oxidized with an oxidizing agent such as hydroperoxide in an inactive solvent at -30 deg.C to 50 deg.C to provide the compound of formula I.
Patients receive acalabrutinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV over 3-4 hours on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2-12, 14, 18, 20, 22, and 24. Cycles repeats every 28 days for up to 24 months or until complete remission is achieved in the absence of disease progression or unacceptable toxicity.
Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous (SC) injection. Dose titration was done to maintain fasting blood glucose of \<140 milligram per deciliter (mg/dL).
The invention relates to a method for simultaneously producing honeysuckle flower distillate and various active substances. The invention relates to a method for simultaneously producing various physiologically active substances such as honeysuckle flower distillate, honeysuckle flower polysaccharide and chlorogenic acid by using honeysuckle flowers as a raw material. The method comprises the steps of vacuum distillation, precipitation separation, macroporous resin separation, and silica gel column separation. The method has the advantages of reasonable design, simple method, and easy popularization. In prior arts, a large amount of organic solvents are adopted for extracting and preparing chlorogenic acid, such that environment pollution is caused; also, the purity is not high, production cost is high, and production efficiency is low. With the method, the problems are solved, and various by-products obtained during honeysuckle flower distillate production process can be comprehensively utilized. Therefore, various physiologically active substances such as honeysuckle flower polysaccharide, high-purity chlorogenic acid, 2-caffeoylquinic acid, 3,4-caffeoylquinic acid and the like are obtained. Therefore, production cost is saved, production efficiency is improved, the process is simple, and the process can easily be applied in industrialized productions. Therefore, raw material utilization rate can be greatly improved.
FIELD: microbiology. SUBSTANCE: invention relates to preparing an antigen from the strain Mycobacterium paratuberculosis ВГНКИ"КА"-ДЕП. Strain is cultured on Watson-Reid medium for 28-35 days. The grown bacterial mass is washed out with distilled water, suspended in physiological solution to concentration 70-90 mg/cm 3  and disrupted by ultrasonic oscillation at 22 kHz for 15-16 min. Cellular detritus is removed by centrifugation at 16 000-20 000 rev/min for 30-60 min and supernatant is preserved with thiomersal at ratio 1: 10 000. Method ensures to obtain more active and specific antigen that can be used for paratuberculosis diagnosis in ruminant animals in РИД. The use of РИД with obtained antigen ensures to detect by 1.4-9.8-fold more sick animals as compared with РСК. EFFECT: improved method of antigen preparing, simplified and accelerated method, decreased cost. 1 tbl, 7 ex
A two-layer gradient coating article is provided that is operable to cause selective adhesion and directional migration of endothelial cells. The first layer includes cell-resisting polymers that repels cells, the second layer includes one layer of peptides that has affinity to and binds specifically to endothelial cells. Furthermore, the peptides are distributed in a gradient in which attached ECs migrate towards the direction of increased concentration, thus enriching the ECs to a desired locus. The combination of a cell-repelling layer and a graded affinity peptide produces a unique result of selective adhesion, directional migration, thus local enrichment of endothelial cells. A method for using such gradient coating article and its potential use in treating cardiovascular diseases are also provided. The invention provides an inexpensive, stable and effective means for attracting ECs to desirable locations.
<P>PROBLEM TO BE SOLVED: To provide antisense oligonucleotides which bind a specific RNA arrangement and also inactivate this.  <P>SOLUTION: Using gene array technology, it is observed that an increase in α4 chain-containing Laminin-8 associated with poor prognosis for patients with brain gliomas. It is established that inhibition of Laminin-8 expression by new generation of highly specific and stable antisense oligonucleotides (Morpholino<SP>TM</SP>) against chains of Laminin-8 can slow or stop the spread of glioma. This has been demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, it has been confirmed that antisense treatment effectively blocks Laminin-8 protein synthesis.  <P>COPYRIGHT: (C)2010,JPO&INPIT